Drugs / 601
last change Jul 2023 re-read 2 minutes ago

601

Developed for
myopic macular degeneration
Investigated by
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04922151 Jun 2021 → Jan 2023 myopic macular degeneration Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 601 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04922151